Loading
A phase 2 trial of Abexinostat in non-Hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT03934567 by Xynomic Pharmaceuticals, Inc., with 87 participants enrolled, started 2020-04-22 and due to reach its primary completion in 2025-01-29. Interventions recorded: Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat, Follicular lymphoma.
Shares Xynomic Pharmaceuticals, Abexinostat, Non-Hodgkin lymphoma (all types).
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.